

Table S18. Summary of druggability and drug development for IPF associated with plasma proteins

Target	Druggability tier	Status	Compound name
MASP1	Tier 3	Approved	Ivacaftor
		Approved	Emtricitabine/Tenofovir
		Approved	Bevacizumab
		Recruiting	OMS-906
		Recruiting	OMS-906
		Recruiting	OMS-906
		Recruiting	OMS-906
WFIKKN2	Tier 3	No ongoing clinical trials	
S100A11	Not currently listed as druggable	No ongoing clinical trials	

Notes: Druggable genes were divided into three tiers, including targets of approved drugs and drugs in clinical trials (tier 1), targets of drugs in clinical trials (tier 2), and targets of drugs in clinical trials (tier 3). IPF: Idiopathic pulmonary fibrosis.

rough MR analysis.

Molecule type	Action type	Study start date
Small molecule	Inhibitor	
Small molecule	Inhibitor	
Biotech	Inhibitor	
Antibody	Inhibitor	01/mar/24
Antibody	Inhibitor	19/fev/24
Antibody	Inhibitor	09/dez/22
Antibody	Inhibitor	27/mar/23

l development (tier 1), proteins closely related to dru

Clinical development activities

Treatment for cystic fibrosis and and prostate cancer

Treatment for immunodeficiency conditions

Treatment for lung cancer

Phase 2: C3 Glomerulopathy (C3G) and Idiopathic Immune Complex-Mediated Glomerulonephritis (ICGN)

Phase 2: Paroxysmal Nocturnal Hemoglobinuria

Phase 1: Paroxysmal Nocturnal Hemoglobinuria

Phase 2: Paroxysmal Nocturnal Hemoglobinuria (PNH) in patients who have a sub-optimal response to ravulizumab

ig targets or with associated drug-like compounds (tier 2), and extracellular proteins and members of key drug-target

==